Abstract:Background: The clinical significance of miR-141-3p in hepatocellular carcinoma has not been verified. Therefore, we conducted this study to examine miR-141-3p expression and its clinical significance in hepatocellular carcinoma and to investigate the functions of its potential targets. Methods: The Cancer Genome Atlas database and the Gene Expression Omnibus database were used to explore the aberrant expression of miR-141-3p in hepatocellular carcinoma. Furthermore, we assessed the miR-141-3p levels in 95 hepatocellular carcinoma tissues with 95 matched adjacent tissues using real-time quantitative polymerase chain reaction. Moreover, a target gene prediction analysis of miR-141-3p, a natural language processing analysis for hepatocellular carcinoma using PubMed, and a gene functional enrichment analysis were conducted to search the potential function of miR-141-3p in the pathogenesis of hepatocellular carcinoma. Results: Regarding The Cancer Genome Atlas data, miR-141-3p levels were markedly downregulated in hepatocellular carcinoma tissue compared to para- or nontumor tissue (4.6112 [1.7096] vs 5.3053 [1.4254], P = .045). MiR-141-3p expression was reduced in patients with hepatocellular carcinoma with a low pathologic T stage (P = .006), a low grade (P = .01), elderly hepatocellular carcinoma patients (P = .001), and male patients with hepatocellular carcinoma (P = .01) compared with that in patients with hepatocellular carcinoma with high pathologic T stages, high grades, young patients with hepatocellular carcinoma, and female patients with hepatocellular carcinoma. However, according to the Gene Expression Omnibus database, no significant differences in the expression of miR-141-3p were observed between hepatocellular carcinoma tissue and normal liver tissue (P = .984). Real-time quantitative polymerase chain reaction confirmed a similar trend of decreased miR-141-3p in hepatocellular carcinoma tissue (1.7542 [0.8663] vs 2.5562 [1.7913], P = .001) as observed in The Cancer Genome Atlas. In addition, decreased miR-141-3p levels were detected in the multiple tumor nodes group (P = .004), the metastasis group (P < .001), and the advanced TNM stage group (P = .01), compared to the single tumor nodes group, the nonmetastasis group, and the early TNM stage group. Two hundred eighty-two genes were identified from the overlap between the predicted targets and the natural language processing analysis. Gene ontology and Kyoto Encyclopedia of Genes and Genomes pathway analyses revealed several significant biological functions and pathways related to the pathogenesis of cancers, including hepatocellular carcinoma. Conclusion: Downregulation of miR-141-3p might be responsible for the carcinogenesis and aggressiveness of hepatocellular carcinoma. MiR-141-3p may act as an antitumor microRNA, which is essential for hepatocellular carcinoma progression through the regulation of various signaling pathways. Thus, interactions with miR-141-3p may provide a novel strategy for hepatocellular carcinoma treatment in the future.

Supplementary Tables S1-S2 from High-Mobility Group Box 1 Promotes Hepatocellular Carcinoma Progression Through Mir-21–Mediated Matrix Metalloproteinase Activity

Supplementary Table 1 from Survivin Expression Is Differentially Regulated by a Selective Cross-talk between RBM38 and miRNAs let-7b or miR-203a

Mir-424-3p Promotes Metastasis of Hepatocellular Carcinoma Via Targeting the SRF-STAT1/2 Axis.

Data from High-Mobility Group Box 1 Promotes Hepatocellular Carcinoma Progression through miR-21–Mediated Matrix Metalloproteinase Activity

Supplementary Tables 1 - 3 from Reversing Effect of Ring Finger Protein 43 Inhibition on Malignant Phenotypes of Human Hepatocellular Carcinoma

Supplementary Tables S1-S3 from Heterochromatin Protein HP1γ Promotes Colorectal Cancer Progression and Is Regulated by miR-30a

High-Mobility Group Box 1 Promotes Hepatocellular Carcinoma Progression Through Mir-21-Mediated Matrix Metalloproteinase Activity

Supplementary Table 4 from LINC00869 Promotes Hepatocellular Carcinoma Metastasis Via Protrusion Formation

Supplementary Table S4 from Receptor-interacting Protein Kinase 2 is an Immunotherapy Target in Pancreatic Cancer

Supplementary Tables from miR-508 Defines the Stem-like/Mesenchymal Subtype in Colorectal Cancer

Supplementary Materials and Methods, Figure Legends, Tables 1 - 9 from Identification of Mir-133B and RB1CC1 As Independent Predictors for Biochemical Recurrence and Potential Therapeutic Targets for Prostate Cancer

The Similar Effects of Mir-512-3p and Mir-519A-2-5p on the Promotion of Hepatocellular Carcinoma: Different Tunes Sung with Equal Skill.

Supplementary Methods, Tables 1 - 6, Figures 1 - 3, PRISMA Checklist from Diagnostic and Prognostic Value of microRNA-21 in Colorectal Cancer: An Original Study and Individual Participant Data Meta-analysis

Supplementary Figure 1 from Mir200c Attenuates P-gp–Mediated MDR and Metastasis by Targeting JNK2/c-Jun Signaling Pathway in Colorectal Cancer

Supplementary Figure 1 from DNA Methylation-Mediated Repression of Mir-886-3p Predicts Poor Outcome of Human Small Cell Lung Cancer

Supplementary Tables 1 - 3 from Pathway-Based Serum microRNA Profiling and Survival in Patients with Advanced Stage Non–Small Cell Lung Cancer

Supplementary Table 1 from An Insertion/Deletion Polymorphism within RERT-lncRNA Modulates Hepatocellular Carcinoma Risk

Supp Table S1, S3-8 from Integrated Genomic and Functional Microrna Analysis Identifies Mir-30-5p As a Tumor Suppressor and Potential Therapeutic Nanomedicine in Head and Neck Cancer

Supplementary Table 6 from <i>linc00869</i> Promotes Hepatocellular Carcinoma Metastasis Via Protrusion Formation

Investigation of Mir-490-3p Expression in Hepatocellular Carcinoma Based on Reverse Transcription-Polymerase Chain Reaction (Rt-Qpcr) and a Meta-Analysis of 749 Cases.

A Qrt-Pcr and Gene Functional Enrichment Study Focused on Downregulation of Mir-141-3p in Hepatocellular Carcinoma and Its Clinicopathological Significance